---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-002225"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:37:31.514176+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Chemomab Therapeutics discloses CFO compensation: $260K salary, 45% bonus, 102,860 ADS options at $1.70

## Summary
- Annual base salary of $260,000 for new CFO Sigal Fattal, plus customary social benefits.
- Yearly bonus potential of 45% of base salary, based on mutually agreed objectives subject to Compensation Committee approval.
- Grant of options to purchase 102,860 American Depositary Shares at $1.70 per ADS, vesting over 4 years.
- Options accelerate upon a change in control (CIC); exercise period extended to 12 months post-termination (except for Cause).

## SEC filing metadata
- accession: 0001178913-23-002225
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/0001178913-23-002225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891323002225/zk2329883.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-002225
- JSON: https://secwatch.observer/filing/0001178913-23-002225.json
- Plain text: https://secwatch.observer/filing/0001178913-23-002225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.